Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).Johann S. de Bono, Mark N. Stein, James Strauss et al.|Journal of Clinical Oncology|2021Cited by 36
A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.Sadhna Shankar, Jim Vasselli, Jon M. Wigginton et al.|Journal of Clinical Oncology|2018Cited by 18
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.Gerald S. Falchook, Anthony J. Olszanski, Jason J. Luke et al.|Journal of Clinical Oncology|2021Cited by 10